WallStreetZenWallStreetZen

NASDAQ: VIRX
Viracta Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for VIRX

Based on 2 analysts offering 12 month price targets for Viracta Therapeutics Inc.
Min Forecast
$4.00+292.16%
Avg Forecast
$5.00+390.2%
Max Forecast
$6.00+488.24%

Should I buy or sell VIRX stock?

Based on 2 analysts offering ratings for Viracta Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VIRX stock forecasts and price targets.

VIRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-12
lockedlocked$00.00+00.00%2023-11-10

1 of 1

Forecast return on equity

Is VIRX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.27%

Forecast return on assets

Is VIRX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VIRX revenue forecast

What is VIRX's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$64.0M
Avg 2 year Forecast
$174.6M

VIRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VIRX$1.02$5.00+390.20%Buy
IPA$1.52$7.00+360.53%Buy
NRXP$0.47N/AN/A
ICCC$5.30N/AN/A
NKGN$1.89N/AN/A

Viracta Therapeutics Stock Forecast FAQ

Is Viracta Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VIRX) stock is to Buy VIRX stock.

Out of 2 analysts, 0 (0%) are recommending VIRX as a Strong Buy, 2 (100%) are recommending VIRX as a Buy, 0 (0%) are recommending VIRX as a Hold, 0 (0%) are recommending VIRX as a Sell, and 0 (0%) are recommending VIRX as a Strong Sell.

If you're new to stock investing, here's how to buy Viracta Therapeutics stock.

What is VIRX's revenue growth forecast for 2026-2027?

(NASDAQ: VIRX) Viracta Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Viracta Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast VIRX's revenue for 2026 to be $2,515,006,673, with the lowest VIRX revenue forecast at $624,431,701, and the highest VIRX revenue forecast at $4,405,581,646.

In 2027, VIRX is forecast to generate $6,856,181,528 in revenue, with the lowest revenue forecast at $2,234,601,495 and the highest revenue forecast at $11,477,761,561.

What is VIRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VIRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VIRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VIRX price target, the average VIRX price target is $5.00, with the highest VIRX stock price forecast at $6.00 and the lowest VIRX stock price forecast at $4.00.

On average, Wall Street analysts predict that Viracta Therapeutics's share price could reach $5.00 by Mar 12, 2025. The average Viracta Therapeutics stock price prediction forecasts a potential upside of 390.2% from the current VIRX share price of $1.02.

What is VIRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VIRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.